Not independent
Tenure on this board
1.1 yrs
Meeting calendar
CAI · Annual meeting · Thursday, June 4, 2026
Caris Life Sciences Inc
10 nominees · 2 ballot items.
Elect ten directors nominated by the Board and ratify Deloitte & Touche LLP as independent registered public accounting firm for fiscal 2026.
Market cap
$4.9B
1Y TSR
-36.9%
Board grade
C-
Record date
Apr 9, 2026
Filing
DEF 14A
Meeting concluded · Jun 4, 2026
Follow how the vote landed and what changed on Caris Life Sciences Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect ten individuals nominated by the Board to serve one-year terms until the 2027 Annual Meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
More detail
The proposal asks shareholders to ratify the Audit Committee’s appointment of Deloitte as Caris’s independent registered public accounting firm for fiscal year 2026. Management is seeking shareholder approval as a governance matter to obtain shareholder input and reaffirm the Audit Committee’s selection; although not legally required, ratification is a common practice. The Audit Committee and Board state that Deloitte’s retention is in the best interests of the Company and shareholders; they note that the committee may change auditors regardless of the vote if it deems appropriate. Context includes a change in auditors in 2024 when EY declined re-engagement and Deloitte was engaged for 2024; fees paid to Deloitte in 2025 were disclosed. The Board recommends a vote FOR and justifies it by the Audit Committee’s oversight and belief that Deloitte’s retention supports the Company’s financial reporting and governance. The proposal is routine and focuses on audit firm ratification rather than substantive governance or compensation changes.
Director elections
Nominees on the ballot10
Independent
Tenure on this board
1.1 yrs
Not independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
1.1 yrs
Not independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
1.1 yrs
Also a director at
Biogen Inc (BIIB)
Independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
1.1 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | FMR LLC | 8.8% | 24,990,017 | $447M |
| 2 | J. H. Whitney Equity Partners VI, LLC | 6.5% | 18,256,615 | $326M |
| 3 | Sixth Street Partners Management Company, L.P. | 4.8% | 13,666,128 | $244M |
| 4 | BRAIDWELL LP | 2.8% | 8,009,447 | $143M |
| 5 | PointState Capital LP | 2.6% | 7,360,446 | $132M |
| 6 | T. Rowe Price Investment Management, Inc. | 2.0% | 5,588,257 | $100M |
| 7 | COATUE MANAGEMENT LLC | 1.9% | 5,291,006 | $95M |
| 8 | COATUE MANAGEMENT LLC | 1.6% | 4,528,986 | $81M |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.5% | 4,324,649 | $77M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3% | 3,758,462 | $67M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Caris Life Sciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.5B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.3B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Caris Life Sciences Inc 2026 annual meeting?
- Caris Life Sciences Inc (CAI) holds its 2026 annual shareholder meeting on Thursday, June 4, 2026.
- What is the record date for the Caris Life Sciences Inc 2026 meeting?
- The record date for the Caris Life Sciences Inc 2026 meeting is Thursday, April 9, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Caris Life Sciences Inc's 2026 meeting?
- The board is presenting 10 director nominees at the Caris Life Sciences Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Caris Life Sciences Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Caris Life Sciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.